drugset

drugset / Trial / NCT00770757

CC-4047 (Pomalidomide) for Graft vs. Host Disease

NCT00770757 ↗

Phase 2 Completed 13 enrolled Washington University School of Medicine

NaSingle-groupOpen-labelTreatment

Summary

This study will test the safety and effectiveness CC-4047 (pomalidomide) in patients with advanced, steroid refractory graft-versus-host disease.

Timeline

Start: 2009-02
Primary completion: 2010-10
Completion: 2011-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pomalidomide	Other / unclassified	2 mg	Oral

Indications